Previous 10 | Next 10 |
Nevro Named to 2022 Bloomberg Gender-Equality Index Leading Indicator Aimed at Increasing Transparency Surrounding Gender-Related Practices and Policies PR Newswire REDWOOD CITY, Calif. , Jan. 26, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a glo...
Nevro Responds to Competitor's Announcement of FDA Approval for Painful Diabetic Neuropathy PR Newswire REDWOOD CITY, Calif. , Jan. 25, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-chan...
Nevro to Report Fourth Quarter and Full-Year 2021 Financial Results Company to Host Conference Call on Wednesday, February 23, 2022 at 1:30 pm PT / 4:30 pm ET PR Newswire REDWOOD CITY, Calif. , Jan. 24, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NV...
Nevro Announces FDA Approval for Expanded Labeling for its 10 kHz High Frequency Spinal Cord Stimulation System for Treatment of Non-Surgical Refractory Back Pain (NSRBP) PR Newswire REDWOOD CITY, Calif. , Jan. 19, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVR...
Clinical Data Presented at 2022 North American Neuromodulation Society (NANS) Annual Meeting Reinforce Significant and Durable Benefits of Nevro's 10 kHz Therapy SENZA-PDN Randomized Controlled Trial Results Demonstrate Significant and Sustained Outcomes with 10 kHz Therapy at 1...
Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2021 Revenue Fourth Quarter 2021 Worldwide Revenue of Approximately $102.5 Million Full-Year 2021 Worldwide Revenue of Approximately $386.6 Million Company Expects to Exceed High End of Previously Provid...
Nevro Announces UnitedHealthcare Coverage for High-Frequency 10 kHz Therapy for the Treatment of Painful Diabetic Neuropathy PR Newswire REDWOOD CITY, Calif. , Jan. 4, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that i...
Nevro Announces Settlement of IP Litigation with Nalu Medical Nevro and Nalu Reached an Agreement to Dismiss Ongoing Litigation Premised on Nalu Medical No Longer Offering a High Frequency SCS Therapy PR Newswire REDWOOD CITY, Calif. , Dec. 21, 2021 /PRNewswi...
CORRECTING AND REPLACING -- Nevro to Present at 40th Annual J.P. Morgan Healthcare Conference PR Newswire REDWOOD CITY, Calif. , Dec. 20, 2021 /PRNewswire/ -- In a release issued under the same headline on December 10, 2021 by Nevro Corp. (NYSE: NVRO), p...
Nevro (NVRO +5.8%) director Kevin C Oboyle bought 2400 shares of the company, as per the SEC statement. At the price range of $83.75-$83.80, Oboyle spent around $201K on shares. The moves takes his direct beneficial ownership to 13,318 shares. Quick look at the company's ownership compos...
News, Short Squeeze, Breakout and More Instantly...
Nevro to Report Second-Quarter 2024 Financial Results and Host Earnings Conference Call on August 6, 2024 PR Newswire REDWOOD CITY, Calif. , July 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-chan...
Nevro to Present at Truist Securities MedTech Conference PR Newswire REDWOOD CITY, Calif. , June 11 , 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chr...
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 PR Newswire REDWOOD CITY, Calif. , May 24, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the trea...